RTP Mobile Logo
Select Publications

Borate U et al. Comparative outcomes and molecular response predictors of IDH1/2-mutated adult acute myeloid leukemia (AML) patients (Pts) after frontline treatment with intensive induction chemotherapy (IC), targeted inhibitors, or hypomethylating agents (HMA) (Alliance). ASH 2021;Abstract 226.

Chen S et al. Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, phase 2 trial. ASH 2021;Abstract 35.

Daver N et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. ASH 2021;Abstract 371.

Daver N et al. Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed/refractory FLT3-mutated acute myeloid leukemia. ASH 2021;Abstract 691.

DiNardo CD et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol 2021;22(11):1597-608. Abstract

DiNardo C et al. A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy-VIALE-A. EHA 2020;Abstract LB2601.

Grenet J et al. Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA + venetoclax as frontline therapy in acute myeloid leukemia. ASH 2021;Abstract 32.

Lancet JE et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2021;8(7):e481-91. Abstract

Matthews A et al. Real world survival outcomes of CPX-351 versus venetoclax and azacitadine for initial therapy in adult acute myeloid leukemia. ASH 2021;Abstract 795.

Minehart JC et al. Incidence and predictors of Sars-Cov-2 antibody responses following COVID-19 vaccination in allogeneic stem cell transplant recipients. ASH 2021;Abstract 2888.

Montesinos P et al. AGILE: A global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. ASH 2021;Abstract 697.

Patel P et al. Ivosidenib (IVO) in combination with azacitidine (AZA) in newly diagnosed (ND) older patients with IDH1 R132-mutated acute myeloid leukemia (AML) induces high response rates: A phase 2 sub-study of the Beat AML Master trial. ASH 2021;Abstract 875.

Pollyea DA et al. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax combined with hypomethylating agents. ASH 2021;Abstract 224.

Pratz KW et al. Cost effectiveness analysis of venetoclax plus azacitidine versus azacitidine in newly diagnosed adult patients with acute myeloid leukemia who are ineligible for intensive chemotherapy from a United States payer perspective. ASH 2021;Abstract 112.

Rautenberg C et al. Real-world experience of CPX-351 as first-line treatment in 188 patients with acute myeloid leukemia. ASH 2021;Abstract 33.

Sekeres MA et al. Pevonedistat (PEV) + azacitidine (AZA) versus AZA alone as first-line treatment for patients with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20-30% marrow blasts: The randomized phase 3 PANTHER trial (NCT03268954). ASH 2021;Abstract 242.

Short NJ et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: Results from a phase I/II study.ASH 2021;Abstract 696.

Wei AH et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood Cancer J 2021;11(10):163. Abstract

Yilmaz M et al. Quizartinib (Quiz) with decitabine (DAC) and venetoclax (VEN) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML) – RAS/MAPK mutations continue to drive primary and secondary resistance. ASH 2021;Abstract 370.

Yilmaz M et al. Hypomethylating agent (HMA) therapy and venetoclax (VEN) with FLT3 inhibitor “triplet” therapy is highly active in older/unfit patients with FLT3 mutated AML. ASH 2021;Abstract 798.